Clinical requirements in the treatment of today's respiratory tract infections
Related Experiment Video
Updated: Aug 31, 2026
Assessing Respiratory Immune Responses to Haemophilus Influenzae
Published on: June 29, 2021
1Department for Cardiopulmonology, University Hospital, University of Berlin, FRG.
Abstract:
Respiratory tract infections (RTIs) are among the most frequent infections in man and lower tract infections account substantially for the overall mortality in hospitals. Regarding the etiology of pneumonias, one has to consider different pathogenic mechanisms, age of the patients, underlying diseases, concomitant medications, symptomatologies, seasonal influences, and clinical conditions, e.g. intensive care environment and mechanical ventilation. To optimize the rational management of respiratory infections, identification of the etiologic agent would be desirable. The decision of how to treat is often based on epidemiologic, clinical, and radiological assessments. Epidemiologic studies have shown a pronounced difference in the etiologic spectrum between community- and hospital-acquired RTIs. In community-acquired pneumonias, pneumococci, Haemophilus influenzae, Legionella, Mycoplasma and viruses predominate, whereas in nosocomially acquired pneumonias, Enterobacteriaceae, e.g. Klebsiella, Proteus, Enterobacter as well as Pseudomonas and staphylococci comprise the most frequent isolates. Empirical therapy has to cover all possible etiologic pathogens which most likely cause the infection. In addition, an adequate kinetic profile, e.g. once or twice daily dosing, sufficient pulmonary tissue or fluid penetration, and acceptable tolerance and costs are prerequisites for optimal therapy. Drugs of choice for the treatment of community-acquired pneumonia are aminobenzylpenicillins or macrolides. Oral cephalosporins exhibit excellent activity against many bacterial pathogens of typical community-acquired pneumonia, and are active against beta-lactamase-producing H. influenzae.
Insights
Respiratory tract infections (RTIs) are common, with lower tract infections causing significant hospital mortality. Identifying the cause is key for effective treatment, differing between community- and hospital-acquired pneumonia.
Area of Science:
- Infectious Diseases
- Pulmonology
- Pharmacology
Background:
- Respiratory tract infections (RTIs) are a leading cause of morbidity and mortality, particularly in hospital settings.
- Understanding the diverse etiologies of pneumonia, influenced by patient factors and clinical environment, is crucial for effective management.
- Differentiating between community-acquired and hospital-acquired RTIs is essential due to distinct causative pathogens.
Purpose of the Study:
- To highlight the importance of identifying the etiologic agent in respiratory tract infections for optimizing treatment.
- To compare the epidemiological and etiological differences between community-acquired and hospital-acquired pneumonias.
- To outline the criteria for selecting optimal antimicrobial therapy for respiratory infections.
Main Methods:
- Review of epidemiological data on common pathogens in community- and hospital-acquired pneumonias.
- Analysis of factors influencing pneumonia etiology, including patient demographics, clinical setting, and prior treatments.
- Evaluation of pharmacokinetic and pharmacodynamic properties, tolerance, and cost-effectiveness of potential antimicrobial agents.
Main Results:
- Community-acquired pneumonias are frequently caused by pneumococci, Haemophilus influenzae, Legionella, Mycoplasma, and viruses.
- Hospital-acquired pneumonias are predominantly caused by Enterobacteriaceae, Pseudomonas, and staphylococci.
- Aminobenzylpenicillins, macrolides, and oral cephalosporins are recommended for community-acquired pneumonia, with cephalosporins effective against beta-lactamase-producing H. influenzae.
Conclusions:
- Accurate diagnosis of the etiologic agent is desirable for rational management of RTIs.
- Treatment decisions should be guided by epidemiological, clinical, and radiological assessments.
- Empirical therapy must cover likely pathogens, considering drug kinetics, tissue penetration, safety, and cost.
More Related Videos
Related Concept Videos
01:25Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
01:19Respiratory Assessment: Purpose and Indications
Objectives and Importance:
The primary goal of respiratory assessment is to evaluate patients at early risk of clinical deterioration. Since respiratory distress often precedes other signs of declining health, breathing patterns and sounds become a...
01:31Common Respiratory Disorders
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:29Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
01:29Microbiota of the Respiratory Tract